Can trazodone be used off‑label to treat anxiety in an adult without contraindications such as recent myocardial infarction, severe hepatic impairment, or a history of serotonin syndrome?

Trazodone for Anxiety: Not Recommended

Trazodone should not be used as a primary treatment for anxiety disorders in adults. While trazodone is FDA-approved only for major depressive disorder 1, it is frequently prescribed off-label for anxiety despite lacking robust evidence for this indication 2, 3.

Evidence Against Use for Anxiety

The most authoritative guidance comes from the 2017 American Academy of Sleep Medicine clinical practice guideline, which explicitly states: "We suggest that clinicians not use trazodone as a treatment for sleep onset or sleep maintenance insomnia (versus no treatment) in adults" 4. This recommendation is particularly relevant because anxiety-related insomnia is a common reason clinicians prescribe trazodone off-label.

Key Problems with Trazodone for Anxiety:

• Lack of efficacy data: The single high-quality study examining trazodone 50 mg showed no clinically significant improvements in sleep outcomes, with reductions in sleep latency (10.2 minutes) and wake time (7.7 minutes) falling below clinical significance thresholds 4

• No systematic evidence: The 2005 NIH State-of-the-Science Conference on Insomnia concluded there is "no systematic evidence for the effectiveness of antidepressants used off-label for the treatment of insomnia" and warned that "risks of use outweighed the benefits" 5

• Widespread off-label misuse: Approximately 85% of trazodone prescriptions (20 million annually in the US) are for off-label indications, primarily insomnia and anxiety, representing $247 million in spending for indications of uncertain clinical value 2

What Should Be Used Instead?

For anxiety disorders, the evidence strongly supports:

First-line pharmacological treatment:

• SSRIs (selective serotonin reuptake inhibitors) are the evidence-based standard for anxiety disorders 6
• These include sertraline, fluoxetine, paroxetine, fluvoxamine, and citalopram

When insomnia accompanies anxiety:

• Short-intermediate acting benzodiazepine receptor agonists (zolpidem, eszopiclone, zaleplon) 7
• Ramelteon for sleep onset issues 4

When depression co-exists with anxiety:

• Full-dose SSRI therapy (not low-dose sedating antidepressants) 7
• Sedating antidepressants like trazodone may be considered as third-line options only when accompanied by comorbid depression AND after other treatments have failed 7

Safety Concerns with Trazodone

Beyond lack of efficacy, trazodone carries significant risks:

• Serotonin syndrome risk: Multiple case reports document serotonin syndrome when trazodone is combined with other serotonergic medications (SSRIs, SNRIs, antipsychotics) 8, 9

• Common adverse effects: In the single controlled trial, 75% of trazodone patients experienced adverse events versus 65% on placebo, with headache (30% vs 19%) and somnolence (23% vs 8%) being most common 4

• Contraindications: Trazodone is contraindicated with MAOIs and requires caution with multiple drug interactions 1

Clinical Algorithm

For an adult presenting with anxiety:

1. First-line: Initiate SSRI therapy at standard doses for anxiety disorders
2. If insomnia is prominent: Add a short-acting benzodiazepine receptor agonist or ramelteon temporarily
3. If depression co-exists: Use full-dose SSRI (not low-dose trazodone)
4. Only consider trazodone if:
   • Patient has failed multiple SSRIs
   • Comorbid depression is present requiring full antidepressant dosing
   • Patient is already on another antidepressant and needs augmentation for sleep
   • Even then, recognize this is off-label use with limited evidence

Common Pitfall to Avoid

The most common error is prescribing trazodone 50-100 mg for "anxiety and insomnia" as a first-line agent. This practice is driven by the perception of trazodone as "safer" than benzodiazepines 4, but this perception is not supported by evidence. At low doses (25-75 mg), trazodone provides only sedation without antidepressant effects 10, and even this sedative effect lacks robust efficacy data for anxiety-related insomnia.

The 2008 insomnia guideline places sedating antidepressants like trazodone as a third-line option, only after benzodiazepine receptor agonists have been tried, and specifically "when used in conjunction with treating comorbid depression/anxiety" 7—meaning as part of comprehensive depression treatment, not as standalone anxiety therapy.